<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483274</url>
  </required_header>
  <id_info>
    <org_study_id>13.0376</org_study_id>
    <nct_id>NCT01483274</nct_id>
  </id_info>
  <brief_title>Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>AML</acronym>
  <official_title>Pharmacologic Upregulation of Cancer Testis Antigens Followed by Vaccine Therapy for Patients With Relapsed Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Acute Myelogenous Leukemia (AML) who relapse after an allogeneic stem cell&#xD;
      transplant cell receive decitabine to up regulate cancer antigen expression, followed by a&#xD;
      donor lymphocyte infusion and an autologous dendritic cell (DC). Vaccine Dendritic cells are&#xD;
      pulsed with overlapping peptides derived from MAGE-A1, MAGE-A3, and NY-ESO-1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For vaccine production, mature DC will be pulsed with overlapping peptides mixes derived from&#xD;
      full-length NY-ESO-1, MAGE-A1, and MAGE-A3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Adult patient population barriers.&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of study treatment</measure>
    <time_frame>4 years</time_frame>
    <description>Tolerance to DAC, at least 50% dosing, and 3 of the 4 planned vaccinations during the first two cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>4 years</time_frame>
    <description>Assessment of Bone Marrow aspiration to check for complete or partial remission, stable disease, and disease progression by bone marrow draws at week 6 and week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>4 years</time_frame>
    <description>Assessment of post-vaccination T cell responses to MAGE-A1, MAGE-A3, and NY-ESO-1 by immunoassay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Safety</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine and donor lymphocyte infused dendritic cell (DC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine</intervention_name>
    <description>Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine</description>
    <arm_group_label>Safety</arm_group_label>
    <arm_group_label>Vaccine</arm_group_label>
    <other_name>DAC</other_name>
    <other_name>Dendritic cells vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for study enrollment:&#xD;
&#xD;
          -  Signed informed consent after discussion of alternative therapies.&#xD;
&#xD;
          -  The first six patients be18 to 65 years old. Patients # 7-10 will range in age from 2&#xD;
             - 65 years.&#xD;
&#xD;
          -  Histologically or cytogenetically confirmed diagnosis of acute myelogenous leukemia&#xD;
             prior to allogeneic SCT, with the following risk factors:&#xD;
&#xD;
               -  &gt; second complete response, or in relapse, at the time of transplant&#xD;
&#xD;
               -  monosomy 5 or 7&#xD;
&#xD;
               -  the presence of a high FLT3/ITD allelic ratio&#xD;
&#xD;
               -  patients with detectable minimal residual disease (MRD) post-transplant&#xD;
&#xD;
               -  &lt; 0.5% positive for recipient leukemia cells by flow cytometry&#xD;
&#xD;
        Inclusion criteria to begin study therapy:&#xD;
&#xD;
          -  Patient is at least three months post-transplant.&#xD;
&#xD;
          -  Patients must be off systemic immunosuppression for at least two weeks prior to the&#xD;
             start of therapy on the study.&#xD;
&#xD;
          -  ECOG performance status 0-2, Lansky performance status &gt;70 (see Appendix 1).&#xD;
&#xD;
          -  Hematologic Function: ANC: ≥ 500; Platelet count: ≥ 75.&#xD;
&#xD;
          -  Renal Function:&#xD;
&#xD;
               -  Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 OR a serum creatinine&#xD;
                  based on age/gender using the Schwartz formula:&#xD;
&#xD;
          -  Cardiac Function: Patient must have normal cardiac function documented within two&#xD;
             weeks before starting of a treatment cycle 1 by:&#xD;
&#xD;
               -  Ejection fraction (&gt; 55%) documented by echocardiogram or fractional shortening&#xD;
                  (≥ 28%) documented by echocardiogram.&#xD;
&#xD;
          -  Liver Function: Total bilirubin ≤ 1.5 x normal for age, and ALT (SGPT) and AST (SGOT)&#xD;
             ≤ 3 x normal for age.&#xD;
&#xD;
          -  Room air pulse oximetry &gt; 94%.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 7 days of enrollment.&#xD;
&#xD;
          -  Male and female patients must agree to use a medically acceptable barrier and/or&#xD;
             chemical contraceptive method during the study and for a minimum of 3 months after the&#xD;
             last dose of chemotherapy on this study.&#xD;
&#xD;
          -  Subjects must be &gt; 3 months and &lt; 12 months post-SCT at the time of the first&#xD;
             vaccination.&#xD;
&#xD;
          -  Donor chimerism must be &gt; 90%, assist at least two weeks prior to beginning treatment&#xD;
&#xD;
          -  Subjects must be at least 30 days post-transplant to enroll on the study and to&#xD;
             undergo apheresis, and must be at least three months post-transplant to begin therapy&#xD;
             with DAC/vaccine.&#xD;
&#xD;
          -  Stem cell donor source may be related or unrelated donor cord blood, related or&#xD;
             unrelated donor bone marrow, and related or unrelated donor peripheral blood stem cell&#xD;
             product. Donors may be no more than two HLA (A, B, C, DR, DQ) antigen mismatched with&#xD;
             the recipient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a history of autoimmune disease, specifically inflammatory bowel disease,&#xD;
             systemic lupus erythematosis, or rheumatoid arthritis.&#xD;
&#xD;
          -  Patient has a known systemic hypersensitivity to DAC, imiquimod, or any vaccine&#xD;
             component.&#xD;
&#xD;
          -  Patient has evidence of recurrent leukemia.&#xD;
&#xD;
          -  Patient is receiving systemic corticosteroids or other immunosuppression.&#xD;
&#xD;
          -  Persistent clinically significant toxicity from prior anticancer therapy that is &gt;&#xD;
             Grade 2 (NCI CTCAE v3.0).&#xD;
&#xD;
          -  Pregnant or lactating females are excluded.&#xD;
&#xD;
          -  Other active systemic malignancy other than leukemia expected to require therapy&#xD;
             within 4 months.&#xD;
&#xD;
          -  Patients with a systemic fungal, bacterial, viral, or other infection not controlled&#xD;
             (defined as exhibiting ongoing signs/symptoms related to the infection and without&#xD;
             improvement, despite appropriate antibiotics or other treatment).&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, would compromise patient&#xD;
             safety or compliance, interfere with consent, study participation, follow up, or&#xD;
             interpretation of study results.&#xD;
&#xD;
          -  Patients with a positive result for any of the following diagnostic tests: Hep B Ag,&#xD;
             Hep B Core Ab, Hep C Ab, HIV-1 Ab, HIV-2 Ab, HTLV-1 Ab, HTLV-2 Ab, RPR.&#xD;
&#xD;
          -  Received any investigational new drug within 30 days prior to the first dose of&#xD;
             vaccine , or are scheduled to receive an investigational new during the course of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G Lucas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

